| |
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility.
|
|
Today’s Big NewsNov 30, 2023 |
|
With Cytiva™️ Protein Select™️ resin, you will finally be able to standardize recombinant protein purification with a platform process. Request information.
|
|
| By Annalee Armstrong By the time GSK sealed the deal on Bellus Health in April, the U.K. pharma knew exactly what not to do with the phase 3 chronic cough program. The company had watched Merck & Co. struggle with a rival med called gefapixant, taking notes. |
|
|
|
By Nick Paul Taylor AbbVie has its eyes on accelerated approval of its c-Met antibody-drug conjugate (ADC). The candidate achieved a 35% response rate in a subset of lung cancer patients, spurring plans to talk to regulators, but unfavorable comparisons to an earlier data drop partly took the shine off the update. |
By Max Bayer Phenomic AI went from radio silence to two deals in two days, this time signing an antibody-focused pact with Astellas. ShapeTX has also been busy, expanding an existing collaboration with Roche to tack on another target. |
Sponsored by WCG Pediatric CGT trials have the potential to cure diseases and prolong lives. Discover steps to protect safety and enhance operations in your CGT trials. |
By Nick Paul Taylor Cybin has put out more data on its psychedelic treatment for depression, presenting clinical data from a phase 2 trial that suggest there may be benefits to repeat administration but not to increasing the dose. |
By Helen Floersh Just as things were getting overheated in the nonalcoholic steatohepatitis (NASH) drug space, GLP-1 receptor agonists showed up to the party with the potential to treat some symptoms of the chronic liver disease. Now, preclinical data from Sagimet Biosciences hints that when it comes to treating NASH, blockbuster GLP-1 drugs like Novo Nordisk’s semaglutide may be more of an ally than a threat to pharma companies pursuing the indication. |
By Helen Floersh New findings from researchers at the University of Montreal Hospital Research Centre suggest that a protein called gp120 might be a key culprit behind comorbidities associated with HIV. |
By James Waldron Against a backdrop of Big Pharma’s slow progress to increase the diversity of clinical trials, Merck & Co. has teamed up with digital health company Acclinate to try and enroll more African American patients in its cancer drug studies. |
By Angus Liu The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere. |
By Conor Hale CrossBay’s approach does away with the metal forceps typically needed to reach the inner uterus and has collected clearances in endometrial biopsies and IVF procedures. |
By Ben Adams As gene therapies ramp up in spinal muscular atrophy and hemophilia, it may soon be the turn of Gaucher disease patients to realize the latent potential of this type of treatment. |
By Angus Liu As industry watchers deliberate the implications from the FDA's investigation into secondary cancer risks from CAR-T medicines, an upcoming expert meeting could offer precious clarity from drug regulators. |
By Dave Muoio The nonprofit will add five new buildings spanning 2.4 million square feet, two of which will be clinical facilities with designs intended to support continuous, tech-enabled care. |
Fierce podcastsDon’t miss an episode |
| This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
